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ABSTRACT 27 
Antibody-dependent cell-mediated cytotoxicity (ADCC) bridges innate and adaptive 28 
immunity, and it involves both humoral and cellular immune responses. ADCC has been 29 
found to be a main route of immune protection against viral infections in vivo. 30 
Haemagglutinin (HA) of influenza virus is highly immunogenic and considered the most 31 
important target for immune protection. Several potent cross-reactive HA-specific 32 
neutralizing monoclonal antibodies (mAbs) have been reported and their conserved 33 
neutralizing epitopes revealed, but there has been no report so far about ADCC epitopes on 34 
HA. Here we identified two dominant ADCC epitopes, designated E1 [Amino acid (AA) 92-35 
117] and E2 (AA 124-159), on HA of pandemic H1N1 influenza virus by epitope mapping of 36 
convalescent plasma IgGs from six H1N1-infected human subjects in China that exhibited 37 
different levels of ADCC activity. E1 and E2 ADCC epitopes overlapped with 38 
immunodominant epitopes of HA. Depletion of purified patient plasma IgGs with yeast cells 39 
expressing E1 or E2 peptides decreased ADCC activity of the IgGs. E1 and E2 sequences 40 
were found to be highly conserved in H1N1 strains, but less so in other subtypes of influenza 41 
A viruses. Our study may aid in designing immunogens that can elicit antibodies with high 42 
ADCC activity. Vaccine immunogens designed to include the structural determinants of 43 
potent broadly neutralizing Abs and ADCC epitopes may confer a comprehensive immune 44 
protection against influenza virus infection.   45 
46 
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INTRODUCTION 47 
Influenza virus infection is one of the most common causes of serious respiratory illness. The 48 
outbreak of a novel H1N1 influenza virus in the year 2009 revitalized the interest to 49 
understand epidemiological and immunological aspects of influenza virus. Virus infection 50 
induces various immune responses, of which humoral immune responses are primarily 51 
responsible for preventive and protective immunity (1, 2). Antibodies against viral antigens 52 
may provide protection either by Fab-mediated neutralizing effect which may interfere with 53 
the binding of virus to the cell surface receptor(s) or block other functionally important viral 54 
structures, or by Fc-mediated effector functions, including antibody-dependent cell-mediated 55 
cytotoxicity (ADCC), phagocytosis, and complement-dependent cytotoxicity (CDC), which 56 
destroy the infected cells. It has been reported that broadly HIV-1-neutralizing human mAb 57 
b12 decreased viral load through ADCC, but not CDC, in passive immunization of rhesus 58 
macaques (3). A follow-up study of the recent RV144 phase III HIV-1 vaccine trial that 59 
demonstrated 31.2% efficacy also suggested that the high level ADCC activity of plasma 60 
samples of the vaccinees inversely correlated with infection risk (4, 5). ADCC against 61 
influenza virus-infected cells was first described by Greenberg et al (6). It was well 62 
documented that the ADCC-mediated clearance of virus-infected cells occurred before 63 
infectious virus particles were released from the infected cells and before other immune 64 
responses, humoral or cellular, were initiated (7). Considering the fact that the ADCC 65 
invokes protective immune response against viral infection (8), ADCC antibody response was 66 
incorporated as one of the important characteristics of potential vaccine candidate by World 67 
Health Organization (9).  68 
A number of HA-specific potent broadly neutralizing mAbs (bnmAbs) have been 69 
reported (10-16). They target conserved epitopes either on HA2 that mediates viral fusion or 70 
on the globular head region HA1 that interacts with the receptor. For example, HA2-specific 71 
bnmAbs CR6261 and F10 recognize conformational epitopes within the conserved A helix, 72 
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while HA2-specific bnmAb 12D1 recognizes a linear epitope within the long CD helix (10, 73 
12, 15). HA1-specific bnmAb 5J8 neutralizes a broad spectrum of 20th century H1N1 viruses 74 
and influenza A(H1N1)pdm virus, and it recognizes a novel and conserved epitope between 75 
the receptor-binding pocket and the Ca2 antigenic site (13). Another HA1-specific mAb C05 76 
neutralizes strains from multiple subtypes of influenza A virus, and it recognizes conserved 77 
elements of the receptor-binding site by a single long heavy-chain complementarity-78 
determining region 3 (HCDR3) loop (14). Like HIV-1 specific bnAbs, influenza virus HA-79 
specific bnAbs are infrequently elicited in natural infection or by vaccine immunization. 80 
Among all influenza virus HA-specific bnmAbs, CH65 may be the only mAb that was 81 
isolated from a vaccinee. CH65 also recognizes the receptor binding pocket on HA1, 82 
mimicking in many aspects the interaction of the physiological receptor, sialic acid, with 83 
HA1 (16). Whether these HA-specific bnmAbs provide immune protection through ADCC 84 
remains to be determined. There has been no report so far about ADCC epitope(s) of 85 
influenza virus HA antigen and their immunogenicity. In this study we screened a panel of 86 
convalescent plasma samples obtained from H1N1-infected human subjects, and identified 87 
two samples with high ADCC activity against pandemic H1N1 influenza virus by using a 88 
fluorescence-based ADCC assay. We did epitope mapping of these two samples, as well as 89 
three other plasma samples with moderate to weak ADCC activity and one plasma sample 90 
with no ADCC activity by using purified IgGs and yeast display technology. We delineated 91 
potential dominant ADCC epitopes by comparing the mapping patterns against different IgG 92 
samples with different levels of ADCC activity.  93 
 94 
MATERIALS AND METHODS  95 
Cell lines, media and reagents. The Raji (CCL-86) cell line was obtained from American 96 
Type Culture Collection (ATCC) and maintained in RPMI 1640 (Invitrogen) containing 10% 97 
heat-inactivated fetal calf serum (FCS) and 2% L-glutamine at 37oC with 5% CO2. The 98 
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following reagents were purchased: penicillin/streptomycin (Sigma), PE labelled anti-human 99 
IgG (Fab’)2 (Jackson ImmunoResearch), FITC labelled anti-c-myc mouse IgG (Sigma), and 100 
fluorescent dyes PKH-67 (Sigma) and 7-AAD (Invitrogen). 101 
Convalescent plasma samples from H1N1-infected human subjects. This research 102 
was authorized by the Institutional Review Board of the University of Hong Kong / Hospital 103 
Authority Hong Kong West Cluster (IRB reference number: UW 11-351). All archived 104 
plasma samples used in the study were obtained from the patients infected with influenza 105 
A(H1N1)pdm virus, which were confirmed by either RT-PCR or viral culture (17). The 106 
median time of plasma collection from the date of onset of infection was 16 months. 107 
Purification of plasma IgGs. Polyclonal IgGs were purified from plasma samples by 108 
Protein G affinity purification. Briefly, plasma samples were thawed, heat inactivated at 56°C 109 
for 45 min, clarified by centrifugation, and filtered through a 0.2 µm mini capsule filter before 110 
loaded onto a Protein G Sepharose  column (GE Biosciences) equilibrated with PBS. IgGs 111 
were eluted with 0.5 M acetic acid (pH 3.0), immediately neutralized with 3M Tris (pH 9.0), 112 
and dialysed against PBS. The purity of polyclonal IgGs was confirmed by reducing and non-113 
reducing SDS-PAGE. 114 
Hemagglutination-inhibition (HAI) assay. HAI assay was performed in V-bottom 115 
96-well microtiter plates as previously described (18). Briefly, non-specific inhibitors were 116 
inactivated by treating each aliquot of plasma sample with receptor destroying enzyme (RDE) 117 
(Denka Seiken, Japan) at a ratio of 1:3 (RDE/plasma) at 37°C overnight. The enzyme was 118 
heat inactivated by incubation at 56°C for 30 min.  Samples were 2-fold serially diluted with 119 
a starting dilution of 1:10. An equal volume of the pandemic H1N1 A/HK/01/2009 virus, 120 
adjusted to approximately 4 HA units/50 μl was added to each well. The plates were covered 121 
and incubated at RT for 1 h followed by addition of 0.5% turkey erythrocytes to the plasma 122 
/virus mixture and further incubation at room temperature for 30 min.  123 
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Neutralization assay. The micro-neutralization assay for the pandemic H1N1 124 
A/HK/01/2009 was carried out in microtiter plates with neutralization of the virus cytopathic 125 
effect as the endpoint in Madin-Darby canine kidney (MDCK) cells described previously 126 
(18). Briefly, serially diluted plasma samples in duplicate with a starting dilution of 1:10 were 127 
mixed with the virus with 100 50% tissue culture infective doses. Following incubation at 128 
37°C for 2h, the plasma / virus mixture were added to MDCK cells. 1 h post infection, the 129 
mixtures were removed, and plasma-free minimal essential medium containing 2 µg/ml of 130 
TPCK (L-1-tosylamide-2-phenylethyl chloromethyl ketone)-treated trypsin (TPCK-Trypsin; 131 
Sigma Immunochemical) was added to each well. The plates were incubated at 37°C for 3-4 132 
days, and the cytopathic effect was recorded and the highest plasma dilution that protected 133 
≥50% of the cells from cytopathology in the wells determined. Positive and negative controls 134 
and virus back titration for confirmation of the viral inoculum were included in each assay. 135 
Preparation of infected target cells. Raji cells were used as target cells in the ADCC 136 
assay and infected target cells prepared as follow. Briefly, Raji lymphoblasts (19) cells were 137 
infected with influenza virus H1N1 A/California/04/2009 at a multiplicity to give about 80-138 
95% infected cells. A sample of target cells was removed 48 h post infection in order to 139 
assess the percent infected cells based on the ability of infected cells to produce 140 
hemadsorption with turkey red blood cells (RBCs), or by flow cytometry using purified IgGs 141 
from H1N1-infected patients. 142 
Flow cytometry of infected target cells. Infected cells were washed twice with PBS 143 
by centrifugation at 400 x g for 5 min, incubated with 5 μg/ml purified IgGs at 4°C for 2 h 144 
followed by washing thrice with FACS buffer (1% BSA in PBS). The cells were then 145 
incubated with PE conjugated to anti-human IgG, F(ab’)2 at 4°C for 1 h followed by washing 146 
twice with FACS buffer and fixation with 2% paraformaldehyde in FACS buffer. The stained 147 
cells were analyzed on a BD flow cytometer and results analyzed by FlowJo software.  148 
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Preparation of effector cells. Peripheral blood mononuclear cells (PBMCs) were 149 
prepared by Ficoll-paque separation of heparinized whole blood obtained from healthy 150 
volunteers and used as effector cells in the ADCC assay. Briefly, the heparinized whole blood 151 
was diluted with an equal volume of PBS containing 10% FCS and 0.5% 152 
penicillin/streptomycin (Pen/Strep). Blood was layered over Ficoll-Paque plus (GE 153 
Healthcare) and centrifuged at 650 x g for 30 min. The PBMCs were harvested and washed 154 
twice with PBS.  155 
ADCC assay. ADCC activity was determined by a flow cytometry-based assay using 156 
two fluorescent dyes to discriminate live and dead cells (20). PKH-67, a membrane labelling 157 
dye, was used to specifically identify the target cells. PKH-67 binds to the cell membrane, 158 
and the dye remains on the cell membrane, even after cell death, avoiding cross-159 
contamination with effector cells. 7-amino-actinomycin-D (7-AAD) is excluded by viable 160 
cells, but can penetrate the cell membrane of dead or dying cells, and intercalate into double 161 
stranded DNA. Briefly, PKH-67-labelled target cells and unlabelled effector cells were 162 
prepared in RPMI 1640 medium containing 10% FCS and 0.5% Pen/Strep to a cell density of 163 
1X 106 cells/ml and 2.5x107 cells/ml, respectively. Purified IgGs were diluted to 5 μg/ml and 164 
1 μg/ml in PBS. 50 μl of target cells were dispensed into a round-bottom 96-well plate in 165 
duplicate followed by addition of 50 μl of 5 μg/ml or 1 μg/ml IgGs, resulting in a final 166 
concentration of 2.5 μg/ml or 0.5 μg/ml IgGs. In the case of plasma samples used in the 167 
assay, plasma samples were diluted to a final dilution of 1:2,000 or 1:10,000. Following 168 
incubation at 37°C for 15 min, 100 μl of effector cells were added to the target cells / IgG or 169 
plasma mixture. Effector cells (pooled PBMCs from three healthy volunteers) and target cell 170 
solutions containing no IgG and IgGs from healthy volunteers were also prepared as controls. 171 
Following 2 h incubation, 1 µl of 7-AAD was added to the wells. Cell death was determined 172 
on a FACS AriaIII flow cytometer using BD FACS Diva software (BD Biosciences, USA). A 173 
total of 5,000 target cells were acquired. Percent cell death was determined by software 174 
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analysis of four identifiable cell populations, live effector cells (no dye), dead effector cells 175 
(7-AAD positive), live target cells (PKH-67 positive) and dead target cells (PKH-67 and 7-176 
AAD double positive). Assay controls used to define cell populations included target cells 177 
alone (background cell death) and target cells with 5 µl Triton X-100 added (maximum 178 
fluorescence). Percent ADCC was calculated as [(% experimental lysis - % spontaneous 179 
lysis) / (% maximum lysis - % spontaneous lysis)]x100, in which “% spontaneous lysis” 180 
referred to percent lysis of infected cells with effectors in the absence of plasma or IgGs, and 181 
“% maximum lysis” referred to percent lysis of infected cells with effectors in the presence of  182 
1% Triton X-100. Experiments were performed in duplicate and repeated once. One 183 
representative set of data was shown in this report.  184 
Construction of HA fragments yeast-displayed library. The gene encoding the 185 
full-length HA of influenza virus H1N1 A/HK/01/2009 was amplified by PCR using a 186 
recombinant plasmid containing the full length HA gene as template and a pair of primers, 187 
HAF (5’-atgaaggcaatactagtagttc-3’) and HAR (5’-ttaaatacatattctacactg-3’) (21). 2 μg of gel-188 
purified HA PCR products was digested with 0.9 units of DNase I (Roche) at 15°C for 15 189 
min in a total volume of 50 μl digestion buffer (50 mM Tris-HCl, pH 7.5, 10 mM MnCl2). 190 
The reaction was stopped by adding EDTA to a final concentration of 50 mM followed by 191 
flash freezing in liquid nitrogen and incubation at 90°C for 10 min to inactivate DNase I. 192 
Randomly digested PCR products were analysed on 2% agarose gel and fragments ranging 193 
from 100 bp to 500 bp in size gel extracted. The gel-purified fragments were blunt ended by 194 
using T4 DNA polymerase (New England Biolabs), and ligated to a modified pComb3X 195 
vector (the multiple cloning sites between two Sfi I sites were replaced with a SmaI 196 
restriction site) digested with Sma I. The blunt end ligation products were electroporated into 197 
TG1 electrocompetent cells, resulting in an HA fragment bacteria library. Recombinant 198 
plasmids were large-scale prepared from the bacteria library using plasmid Maxi-prep kit 199 
(QIAGEN) and  the inserts amplified by PCR using three sense primers, 3XYDF1 (5’-200 
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tattttctgttattgcttcagttttggcccaggcggcc-3’), 3XYDF2 (5’-201 
tattttctgttattgcttcagttttCggcccaggcggcc-3’) and 3XYDF3 (5’-202 
tattttctgttattgcttcagttttCCggcccaggcggcc-3’), paired with three antisense primers, 3XYDR1 203 
(5’-accctcagagccaccactagttggccggcctggcc-3’), 3XYDR2 (5’-204 
accctcagagccaccactagttgggccggcctggcc-3’) and 3XYDR3 (5’-205 
accctcagagccaccactagttGgggccggcctggcc-3’). Each sense primer was paired with each 206 
antisense primer in the PCRs in order to avoid any clonal loss resulting from open-reading 207 
frame shift either in the fragment region or in the C-terminal myc tag region or both in the 208 
final yeast display library. All PCR products were gel-purified and re-amplified by PCR 209 
using high-fidelity DNA polymerase (Invitrogen) and a pair of primers, YDRDF (5'-210 
cttcgctgtttttcaatattttctgttattgcttcag-3’) and YDRDR (5’-211 
gagccgccaccctcagaaccgccaccctcagagccaccactag-3’), to add two overhang regions for 212 
homolog recombination with linearized yeast display plasmid pYD7, a modified vector of 213 
pCTCON2 (22). The following PCR program was used for re-amplification of the inserts: an 214 
initial denaturation at 95°C for 3 min followed by 20 cycles of (95°C, 30s, 58°C, 30s, 72°C, 215 
30s) and a final extension at 72°C for 10 min. The amplified inserts were mixed with 216 
linearized PYD7 plasmid DNA at a ratio of 3:1 (12 μg of inserts were mixed with 4 μg of 217 
linearized pYD7), and electroporated into yeast competent cells, EBY100, by the Li-Ac 218 
method (23). The resultant yeast library contained 5 million individual recombinant yeast 219 
clones. Following amplification, recombinant yeast cells were aliquoted and preserved in 220 
SDCAA medium supplemented with 15% glycerol at -80°C. Each aliquot contained 100 221 
million yeast cells in 1 ml frozen medium. 222 
Yeast library sorting and flow cytometry of monoclonal yeast. Induction of 223 
expression of HA fragments on yeast cell surface was performed by following the protocol 224 
provided by Wittrup's group (22). Recombinant yeast cells were grown in SDCAA medium 225 
(yeast nitrogen-based casamino acid medium containing 20 g/l glucose) at 30°C for 24 h with 226 
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shaking and passaged once with fresh medium to eliminate dead cells. The yeast cells were 227 
centrifuged and resuspended in SGCAA medium (yeast nitrogen-based casamino acid 228 
medium containing 20g/l galactose) to an optical density at 600 nm (OD600nm) of 0.5-1.0, 229 
and then induced at 20°C for 36-48 h with shaking. The induced yeast population were 230 
subject to sorting against purified IgGs as follow. The induced recombinant yeast population 231 
were stained with a final concentration of 500 nM purified IgGs by incubation at 4°C for 3 h. 232 
Following washing twice with cold PBS, yeast cells were incubated with PE conjugated to 233 
goat anti-human IgG, (Fab’)2 and FITC conjugated to mouse anti-c-myc IgG at 4°C for 1 h. 234 
Following washing thrice with cold PBS, yeast cells were sorted using FACS Aria III (BD 235 
Biosciences) for PE and FITC double positive populations. PE and FITC labelled beads and 236 
unstained yeast library were used for calculation of compensation prior to sorting. The same 237 
gate was used for sorting recombinant yeast library stained with different polyclonal IgGs. 238 
For each polyclonal IgG sample 3-5×105 yeast cells were sorted. Double positive population 239 
were verified by flow cytometry of randomly picked monoclonal yeast from the population 240 
using the same primary and secondary antibodies as described above.  241 
DNA sequencing and epitope mapping. Recombinant yeast plasmids were extracted 242 
from each sorted yeast library using yeast cell plasmid extraction kit (Omega Bio-Tek) and 243 
electroporated into E. coli TG1 electrocompetent cells. More than 300 ampicillin resistant 244 
yeast clones from each sorted library were sequenced using primers annealing to pYD7 and 245 
the sequences analysed. The recombinant clones with the inserts in the HA open-reading 246 
frame and with productive Aga2-C-myc tag were considered positive clones. The deduced 247 
amino acid (AA) sequences of positive clones were used for epitope mapping 248 
(http://insilico.ehu.es/translate/) against HA sequence of Influenza virus H1N1 249 
A/HK/01/2009 (GenBank: ACR18920.1). The insert sequences with less than 4 AAs in 250 
length, or identity rate below 75%, were excluded from the analysis. About 100-150 valid 251 
positive clones were identified for each plasma IgG sample. The frequency of each AA 252 
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presented in the valid positive clones was counted and calibrated for the same total number of 253 
5,000 AAs for each IgG sample.  254 
Depletion of purified IgGs with recombinant yeast expressing E1 or E2. 108 255 
recombinant yeast cells surface-displaying E1 or E2 were washed with PBS twice by 256 
centrifugation at 2000 x g for 5 min, and incubated with 500 μg of IgGs M1036 or M1037 at 257 
a total volume of 1 ml in PBS at 4°C overnight. Yeast cells were pelleted by centrifugation at 258 
2000 x g for 5 min and the supernatant transferred to a new preparation of 108 recombinant 259 
yeast cells surface-displaying E1 or E2 and incubated at RT for 1 h. Yeast cells were pelleted 260 
by centrifugation at 2000 x g for 5 min and the supernatant collected in new tubes. Sequential 261 
depletion with E1 and E2 was carried out by switching the recombinant yeast expressing E1 262 
or E2 in the second round of depletion followed by additional round of depletion with the 263 
same recombinant yeast. Antibody concentrations in the depleted IgG samples were 264 
determined by measuring OD280nm using Nanodrop.  265 
 266 
RESULTS 267 
Characterization of patient plasmas. Seven convalescent plasma samples were 268 
characterized for hemagglutination inhibition (HAI) and neutralization activities (Fig. 1). All 269 
plasma samples had an HAI titre ≥ 1:160, with plasma M1024 having the highest HAI titre of 270 
1:1,280 (Fig. 1). All plasma samples showed similar neutralization endpoint dilution (NI) 271 
titers. Plasma M1017 and M1039 had an NI titer of 1:160, while all others 1:320 (Fig. 1). 272 
Polyclonal antibodies were purified from these plasma samples and the binding of purified 273 
IgGs to H1N1-infected target cells confirmed by flow cytometry (Fig. 2). All IgG samples 274 
showed similar binding activity at 10 μg/ml except that M1081 IgGs showed relatively high 275 
binding to the infected target cells (Fig. 2). ADCC activity of 1:10,000 and 1:2,000 diluted 276 
plasmas was then measured by a flow cytometry-based ADCC assay. Percent increase in 277 
cytotoxicity of infected target cells in the presence of five out of seven diluted plasma 278 
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samples was observed (Fig. 3A). Three plasma samples, M1036, M1037 and M1024, 279 
exhibited high cytotoxicity activity at one or both dilutions. Plasma M1039 and M1081 also 280 
showed cytotoxicity activity that was above the average (%ADCC=10%), while the 281 
remaining two plasma samples, M1017 and M1089, did not show ADCC activity. To confirm 282 
that the IgGs in the plasma samples contributed to the observed cytotoxicity, purified IgGs at 283 
concentrations (0.5 μg/ml and 2.5 μg/ml) that were equivalent to the antibody concentrations 284 
in the diluted plasmas were tested in the same ADCC assay (Fig. 3B). The result was largely 285 
consistent with that using the diluted plasma. Five out of seven samples, IgGs M1036, 286 
M1037, M1039, M1017 and M1024, had above-average ADCC activity (10%) at one or both 287 
antibody concentrations, while two samples, IgGs M1081 and M1089 had below average 288 
cytotoxicity (Fig. 3B). Discrepancy between the two sets of data was observed with sample 289 
M1017. Plasma M1017 had no or negative cytotoxicity, but its purified IgGs had above 290 
average cytotoxicity (Fig. 3). Based on the percent ADCC tested with the purified IgGs, we 291 
categorized six IgG samples into three groups: ADCC++ (M1036, M1037), ADCC+ (M1017, 292 
M1024 and M1039), and ADCC- (M1089). All six IgG samples were subject to epitope 293 
mapping by yeast display. Sample M1081 was excluded in the further analysis for its below 294 
average or negative ADCC activity in both assays. 295 
Construction of recombinant yeast library and sorting induced yeast library 296 
against six IgG samples. To assess the quality of HA fragments recombinant yeast library, 297 
we sent over 100 random yeast clones for DNA sequencing. The inserts with a length ranging 298 
from 50 bp to 750 bp and an average length of 146 bp were distributed over the full length 299 
HA ectodomain with no significant bias to certain region(s) although two hot spots at AA 300 
position 162-179 and 464-481 were observed (data not shown). The yeast library was induced 301 
to express HA fragments on cell surface and the induced yeast library stained were incubated 302 
with individual IgG samples as a primary antibody and PE-anti-human IgG, F(ab’)2 and 303 
FITC-anti-c-myc as secondary antibodies. PE and FITC double positive yeast cells were 304 
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sorted and amplified. 20-30 monoclonal yeast were randomly picked from each sorted library 305 
and tested by flow cytometry for expression of c-myc and for binding to the IgG sample used 306 
for sorting. About 50 % monoclonal yeast clones were positive for binding to the IgGs (mean 307 
value two times higher than mouse IgG isotype control). All positive yeast clones were sent 308 
for DNA sequencing, and 35-50 % of which had an insert that was in HA open reading frame. 309 
Based on the small scale sequencing result, a total of 300-350 monoclonal yeast were picked 310 
from each sorted library and sent for DNA sequencing, and about 100-150 valid positive 311 
clones were obtained from each sorted library.  312 
Epitope mapping of purified IgGs and identification of dominant ADCC epitopes 313 
on H1N1 HA. For each IgG sample, the AA sequences of all valid positive clones were 314 
mapped to the HA sequence of Influenza virus H1N1 A/HK/01/2009 (GenBank: 315 
ACR18920.1) and the frequency of each AA counted and calibrated, so that for each IgG 316 
sample there were 5,000 AAs in total. The calibrated AA frequencies for each IgG sample 317 
were then plotted onto H1N1 HA sequence (Fig. 4A). We observed three immunodominant 318 
epitopes that had an average AA frequency over 10 for three or more IgG samples. Two 319 
immunodominant epitopes, HA-E1 (AA 92-117) and HA-E2 (AA 124-159), were located on 320 
HA1 region, and the third one, HA-E3 (AA 470-521), on HA2 region. To localize ADCC 321 
epitopes, the calibrated AA frequencies for each position within the same ADCC group were 322 
averaged and the averaged AA frequencies for each ADCC group re-plotted (Fig. 5B). The 323 
first two immunodominant epitopes, HA-E1 and HA-E2, had an average AA frequency that 324 
was two-fold higher in the ADCC++ or ADCC+ group than that in the ADCC- group 325 
(TABLE 1), suggesting that HA-E1 and HA-E2 may be two dominant ADCC epitopes. The 326 
third immunodominant epitope HA-E3 showed an average AA frequency that was more than 327 
two-fold higher in the ADCC- group than that in the ADCC++ or ADCC+ groups (TABLE 1).  328 
Confirmation of dominant ADCC epitopes on HA. To comfirm possible ADCC 329 
epitopes, we expressed HA-E1 and HA-E2 on yeast cell surface and used the recombinant 330 
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yeast to absorb two IgG samples in ADCC++ group, IgGs M1036 and M1037. The IgGs 331 
absorbed with HA-E1 or HA-E2 alone showed significantly decreased ADCC activity 332 
compared to the original IgG samples and the IgGs absorbed with HA-E3 expressed on yeast 333 
cell surface (Fig. 5). Sequential absorption with recombinant yeast expressing HA-E1 and 334 
HA-E2 almost abolished the ADCC activity of the two IgG samples, confirming that HA-E1 335 
and HA-E2 may be dominant ADCC epitopes on HA and antibodies specific for HA-E1 and 336 
HA-E2 peptides may have high ADCC activity (Fig. 5). We observed that IgG 1037 absorbed 337 
with E3-expressing yeast also showed decrease in ADCC activity, presumably due to the 338 
removal of E3-binding antibodies that may affect the ADCC activity, but the decrease in 339 
ADCC activity caused by the absorption with E1 or E2-expressing yeast was more than 2-340 
fold more. 341 
Conservation of HA-E1 and HA-E2 epitopes. We first analyzed the conservation 342 
rate of HA-E1 and HA-E2 sequences in H1N1 strains circulating in 2007-2009. A total of 343 
2408 H1N1 HA sequences downloaded from Los Alamos Influenza Research Database 344 
(http://www.fludb.org/brc/home.do?decorator=influenza) were included in the analysis 345 
(TABLE 2). We found that both E1 and E2 were highly conserved in 2009_H1N1 strains 346 
with average AA conservation rate reached 95% and 94%, respectively. E1 and E2 were 347 
relatively conserved in 2007_ and 2008_H1N1 strains with average AA conservation rate 348 
over 70%. Mutations occurred mainly at 6 AA positions of E1 and 11 of E2 with a 349 
conservation rate of each AA below 15% (TABLE 2). We then analyzed the conservation 350 
rate of E1 and E2 in 2,325, 1,339 and 7,880 influenza A viruses (IFA) isolated in 2007, 2008 351 
and 2009, respectively. A total of 11,544 IFA HA sequences downloaded from the Los 352 
Alamos Influenza Research Database were included in the analysis (TABLE 2). We found 353 
that both E1 and E2 were also conserved in IFAs circulating in 2009 with an average 354 
conservation rate over 80%, but much less so in IFAs circulating in 2007 and 2008 with an 355 
average conservation rate below 60% (TABLE 2). We found that a few residues in E1 and E2 356 
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were well conserved with no change in all reported HA sequences of IFAs, including E98, 357 
C107, Y108 and P109 in E1, and G148 and C153 in E2 (TABLE 2), suggesting their 358 
importance for HA structural integrity and / or function. 359 
  360 
DISCUSSION 361 
Both neutralizing and non-neutralizing antibodies may confer cytotoxicity effect largely 362 
depending on antibody affinity for Fc gamma receptors (FcrRs) (24-28). The four subclasses 363 
of human IgG differ from each other in the cytotoxic potency due to their different affinities 364 
for FcrRs. In general, the rank order is IgG1 (+++) = IgG3 (+++) > IgG2 (+/-) ≥ IgG4 (+/-) 365 
for ADCC. IgG1 and IgG3-mediated ADCC rely on FcrRIIIa that mainly expresses on NK 366 
cells and FcRI that expresses on monocytes. Although ADCC activity is mediated by the Fc 367 
region, the Fab region of IgG that binds to the antigen expressed on the surface of target cells 368 
may affect Fc-mediated ADCC activity (29, 30). The mechanism for Fab effect on ADCC 369 
remains to be elucidated. In this study, we purified plasma antibodies by using Protein G 370 
affinity column, which purified all four IgG subclasses. In human sera, IgG1 is the most 371 
abundant subclass and accounts for 66% of total IgGs, while IgG2, IgG3, IgG4 account for 372 
23%, 7% and 4%, respectively. Therefore, the ADCC activity detected in this study was 373 
mediated mainly by IgG1s. Similar binding activity of purified IgGs to H1N1-infected Raji 374 
cells as measured by flow cytometry suggests that different ADCC activities of different 375 
convalescent plasma IgG samples may be attributed to different epitopes recognized by the 376 
purified IgGs. Two dominant ADCC epitopes on HA were identified by differential epitope 377 
mapping of plasma IgGs with different ADCC activities, and confirmed by using epitope-378 
expressing recombinant yeast depleted IgGs in the same ADCC assay. E1 has 26 AAs and E2 379 
36 AAs in length, suggesting that they may not be a single epitope, but multiple epitopes 380 
instead, and that both E1 and E2 may not be linear epitopes. Depletion of plasma IgGs with 381 
E2-expressing recombinant yeast seems more effective than that with E1-expressing 382 
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recombinant yeast (Fig. 5), suggesting that E2 may be more important than E1 in eliciting 383 
antibodies with ADCC activity. The seven human individuals were infected with same H1N1 384 
strain, but the ADCC activity of their plasmas and purified IgGs were different, and the 385 
difference did not seem to correlate with the HAI and NI titers of the plasma (Fig. 1 and 3). 386 
The mechanism for the different antibody profiles and different ADCC activities in different 387 
individuals infected with the same virus strain requires further study. The patients included in 388 
this study presented mild symptoms and recovered from influenza virus infection during the 389 
outbreak of swine flu in 2009. Their plasma had a similar NI titre, but different ADCC 390 
activity. It would be interesting to determine how much the ADCC activity of the plasma 391 
IgGs contribute to the control of virus infection. We observed that patient M1024 plasma had 392 
an HAI titer which was significantly higher than that of other plasmas, but purified IgG 393 
M1024 showed moderate ADCC activity and an average neutralization activity. It would be 394 
also interesting to determine if and how HAI activity of the plasma contributes to the control 395 
of virus infection. The discordance between HAI and neutralization assay results has been 396 
observed in our previous study (18), and could be explained by several mechanisms. The HAI 397 
assay measures HA-specific antibodies in binding to HA and interfering with virus 398 
agglutination with RBC, while the neutralization assay using live virus measures the capacity 399 
of total antibodies (not only HA-specific antibodies) for inhibiting the entry of virus to target 400 
cells. The antibodies that neutralize virus may not inhibit hemagglutination and hence are not 401 
detected by the HAI assay. Similarly, antibodies that inhibit hemagglutination may not have 402 
viral neutralizing activity and therefore are not detectable by the neutralization assay. In 403 
addition, virus strains, host source of the red blood cells and other non-specific inhibitors may 404 
also affect the binding avidity in HAI assay. Sequence conservation analysis showed that E1 405 
and E2 were highly conserved in H1N1 strains. Although the conservation rates of E1 and E2 406 
were not high in other subtypes of influenza A viruses, we identified some well conserved 407 
residues in both E1 and E2, which may be useful for designing subtype-specific vaccine 408 
17 
 
immunogens. The identification of dominant ADCC epitopes on H1N1 HA shown in this 409 
study may help develop universal vaccine that confers comprehensive protection against 410 
influenza virus infection.  411 
In this study, we used H1N1-infected target cells in the ADCC assay. Both HA and 412 
neuraminidase (NA) were antigenic determinants for ADCC antibodies, but NA was found to 413 
be a minor ADCC determinant (31). The ectodomain of matrix protein 2 (M2e) of influenza 414 
A virus has been suggested to be an attractive target for a universal influenza A vaccine 415 
because M2e sequence is highly conserved in influenza virus subtypes. Intraperitoneal or 416 
intranasal administration of M2e-based proteins / particles to mice provided 90-100% 417 
protection against a lethal virus challenge and the protection was mediated by antibodies (32, 418 
33). But the immunogenicity of M2e alone is very weak and natural infection with influenza 419 
A viruses usually does not induce significant M2e-specific antibodies. We tested the binding 420 
of all seven convalescent plasma IgGs to recombinant M2e by ELISA and the titers were 421 
overall low (data not shown). We cannot exclude the possibility that M2e-specific antibodies 422 
present in IgGs M1036 and M1037 may contribute to the killing of H1N1-infected cells, but 423 
considering the overall low titer of M2e-specific antibodies in the plasmas, and supposedly 424 
restricted accessibility of M2e-specific antibodies to M2 on the infected cell surface in the 425 
presence of HA-specific antibodies, we assume that M2e-specific antibody mediated ADCC 426 
activity in IgGs M1036, M1037 and other IgG samples may be minimal.  427 
Various ADCC assays have been reported that differ mainly in the usage of effector 428 
cells and measurement of ADCC activity. The most popular assay was the radioactive 429 
chromium (51Cr)-release assay, which was first developed in 1968 (34). The assay was based 430 
upon the passive internalization and binding of 51Cr of sodium chromate to target cells. Lysis 431 
of the target cells by effector cells resulted in the release of the radioactive probe into the cell 432 
culture, which can be detected by a γ-counter. This assay was considered a ‘gold standard’ to 433 
measure cell-mediated cytotoxicity. The 51Cr release assay usually takes about 6 to 24h to 434 
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complete depending on the type of cells, amount of labelling and activity measurement.  This 435 
assay has a number of disadvantages, including low sensitivity, poor labelling and high 436 
spontaneous release of isotope from some target cells. Additional problems with the 51Cr-437 
release assay include biohazard and disposal problems with the isotope. To avoid these 438 
limitations several other methods have been developed to assess ADCC activity. These 439 
assays are based on the release of nonradioactive compounds from target cells, or detection of 440 
enzymatic activity in target cells, or cell-based assays to detect dying or dead target cells by 441 
fluorometry or flow cytometry. In this study we tested convalescent human plasma and 442 
purified polyclonal IgGs in a flow cytometry-based ADCC assay by differential identification 443 
of live and dead cells. We used PBMCs from healthy donors as effector cells and directly 444 
measured the dead infected cells in the presence of plasmas or IgGs. The 7AAD dye used in 445 
this assay to discriminate live and dead or dying cells can easily pass through a dead or dying 446 
cell and intercalate with DNA. Whereas the assays based on the release of nonradioactive 447 
compounds and enzymes from target cells to culture medium require complete lysis of the 448 
target cells (20). We used NK-resistant Raji cells as target cells in this study. Unlike MDCK 449 
cells, influenza virus infected Raji cells do not grow fast and have low background cell death 450 
in the absence of antibodies, which makes Raji an ideal cell line for the ADCC assay. In 451 
contrast, influenza virus infected MDCK cells grow fast and massive cell death occurs in the 452 
absence of antibodies, which gives rise to high background cell death and makes it very 453 
difficult to optimize the conditions for the ADCC assay. In the present study, for some 454 
samples, we observed that more diluted plasma exhibited higher ADCC activity than less 455 
diluted plasma, and IgGs at a low concentration led to higher ADCC activity than the IgGs at 456 
a high concentration (Fig. 3A, 3B). The same phenomenon was also observed in other studies 457 
(29, 30). It has been reported that the overall concentration of polyclonal IgGs affect 458 
inversely the ADCC effect. However, it varies with immune status of the subjects and epitope 459 
availability on the surface of the target cells. There is no conclusive study indicating the 460 
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correlation of concentration of IgG with ADCC activity. Saturation of antibodies, 461 
interference of non-ADCC antibodies present in the polyclonal antibodies, and variation of 462 
PBMCs may all contribute to this phenomenon (25, 35, 36).  463 
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FIGURE LEGEND 475 
FIG 1 HAI and NI titers of convalescent plasma samples from seven H1N1-infected 476 
human subjects. Each plasma sample was tested for anti-HA antibodies by HAI assay. The 477 
NI titer was determined against pandemic H1N1 A/HK/01/2009 virus. 478 
FIG 2 Binding of purified IgGs to H1N1-infected Raji cells by flow cytometry. All IgG 479 
samples were tested at 10 μg/ml. Nonspecific IgG sample was a secondary antibody only 480 
control (without a primary antibody added). 481 
FIG 3 Percent ADCC of seven convalescent plasma samples and their purified IgGs. 482 
(A): Plasma samples were diluted 1:10,000 and 1: 2,000. (B): Purified IgGs were tested at 0.5  483 
μg/ml and 2.5 μg/ml. Each sample was tested in duplicate and the average standard variation 484 
was 5% as displayed in the error bars.  485 
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FIG 4 Epitope mapping of six purified IgG samples. A: The AA frequencies for all six 486 
IgG samples were mapped onto HA ectodomain. B: Six IgG samples were grouped into 487 
ADCC++ (M1036 and M1037), ADCC+ (M1024, M1027 and M1039) and ADCC- (M1089) 488 
samples, and the AA frequencies averaged in each group and mapped to H1N1 HA 489 
ectodomain. Y axis represents the frequency of each AA in positive clones. X axis represents 490 
AA position on H1N1 HA. 491 
FIG 5 Percent ADCC of IgGs M1036 and M1037 after depletion with monoclonal yeast 492 
expressing E1, or E2, or both. Each depleted IgG sample was tested at a final concentration 493 
of 2.5 μg/ml. Undepleted IgGs M1036 and M1037, and IgGs M1036 and 1037 depleted with 494 
recombinant yeast expressing E3 were included as controls. 495 
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TABLE 1 Average AA frequency of three immunodominant epitopes on H1N1 HA. 
HA 
Epitopes 
AA 
position AA Sequence 
Average AA Frequency 
ADCC++ 
(M1036 and 
M1037) 
ADCC+ 
(M1024, M1017 
and M1039) 
ADCC- 
(M1089) 
HA-E1 92-117 SWSYIVETSSSDNGTCYPGDFIDYEE 51.86±3.16 38.21±0.72 24.11±2.55 
HA-E2 124-159 SVSSFERFEIFPKISSWPNHESNKGVTAACPHAGAK 20.66±2.23 32.14±2.93 10.25±1.19 
HA-E3 470-521 
LKNNAKEIGNGCFEFYHKCDN
TCMESVKNGTYDYPKYSEEA
KLNREEIDGVK 
15.57±1.45 6.54±1.17 40.17±4.09 
 
 
TABLE 2 Sequence conservation of E1 and E2 in H1N1 strains and all subtypes of 
influenza A viruses (IFAs) circulating in 2007, 2008 and 2009. In parenthesis: number of HA 
sequences included in the sequence analysis. 
 
 
 
 
 
AA position 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117
AA sequence S W S Y I V E T S S S D N G T C Y P G D F I D Y E E
2007_H1N1 
(1,000)
100 100 100 100 100 94 100 67 8 1 8 2 100 100 98 100 100 100 100 2 100 5 98 100 100 100 76
2008_H1N1 
(408)
100 100 100 100 99 93 100 13 11 1 13 6 100 100 96 100 100 100 100 7 100 8 94 100 99 100 75
2009_H1N1 
(1,000) 100 100 100 100 100 100 100 81 80 80 81 76 100 100 100 100 100 100 100 81 100 81 98 100 100 100 95
2007_IFA 
(2,325)
33 98 64 64 65 87 100 16 29 13 4 1 63 44 25 100 100 100 67 38 50 2 79 81 67 64 56
2008_IFA 
(1,339)
41 98 65 65 67 89 100 7 32 10 6 2 63 51 36 100 100 100 68 39 54 3 77 84 68 65 57
2009_IFA 
(7,880) 86 100 90 90 90 97 100 79 87 78 79 77 89 87 85 100 100 100 90 87 88 78 94 97 90 89 89
AA position 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159
AA sequence S V S S F E R F E I F P K T S S W P N H D S N K G V T A A C P H A G A K
2007_H1N1 
(1,000)
98 100 100 100 99 99 95 100 100 100 100 100 100 1 93 99 100 100 98 100 3 0 2 5 100 97 8 98 8 100 3 95 2 100 7 0 70
2008_H1N1 
(408)
96 99 100 100 100 99 97 100 100 98 100 100 99 2 90 100 100 100 96 100 7 0 6 5 100 96 13 96 13 100 6 93 7 100 9 1 70
2009_H1N1 
(1,000) 100 100 100 100 100 100 100 100 100 98 100 100 100 81 99 100 100 100 100 100 81 78 81 81 100 99 81 100 81 100 80 100 81 100 81 81 94
2007_IFA 
(2,325)
68 25 29 31 55 89 37 33 33 54 39 62 51 0 52 48 97 25 33 48 13 5 6 2 100 56 14 25 72 100 30 23 8 52 10 1 40
2008_IFA 
(1,339)
73 36 37 39 57 89 43 40 40 56 47 62 54 1 52 50 97 38 39 53 10 3 6 3 100 57 14 36 68 100 23 31 10 56 8 1 42
2009_IFA 
(7,880) 95 85 85 85 89 98 86 85 86 87 87 89 87 77 85 88 99 85 85 87 79 76 78 78 100 87 81 85 94 100 81 84 79 88 79 78 86
Average 
rate 
Average 
rate 
HA-E1
HA-E2
